Alkali Metal Or Alkaline Earth Containing Patents (Class 424/722)
  • Patent number: 10400198
    Abstract: A method of sanitizing a surface is described that includes: (a) providing a pH control composition that includes at least one pH control agent (such as sodium bisulfate); (b) contacting a first feed aqueous stream with the pH control composition, thereby forming a first treated aqueous stream; (c) combining at least a portion of the first treated aqueous stream with a feed sanitizing aqueous stream that includes free available halogen, thereby forming a treated sanitizing aqueous stream that includes free available halogen (such as free available chlorine). The surface sanitizing method further includes, (d) elevating the temperature of the treated sanitizing aqueous stream, thereby forming a heated treated sanitizing aqueous stream having an elevated temperature that includes free available halogen. The heated treated sanitizing aqueous stream is applied to a surface to be sanitized (such as a poultry carcass surface).
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: September 3, 2019
    Assignees: EAGLE US 2 LLC, SOUTHEASTERN SYSTEMS, INC.
    Inventors: Richard H. Ferguson, Christopher M. Kareis, Walter Neal Stanford, Michael Eugene Allen
  • Patent number: 10294457
    Abstract: The present invention relates to directed differentiation and maturation of hepatocyte-like cells. In particular, the present invention relates to exposure of hepatocyte-like cells to an activator of a retinoic acid responsive receptor, such as retinoic acid (RA), optionally in combination with an inhibitor of GSK-3 (Glycogen synthase kinase 3) or activator of Wnt signalling and/or with the overlay of the cells with one or more components characteristic of the mammalian extracellular matrix (matrix overlay). The present invention also relates to exposure of hepatocyte-like cells to an activator of a retinoic acid responsive receptor, such as retinoic acid (RA), optionally in combination with an inhibitor of a cycline dependent kinase (CDK) and/or with the overlay of the cells with one or more components characteristic of the mammalian extracellular matrix (matrix overlay).
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: May 21, 2019
    Assignee: Takara Bio Europe AB
    Inventors: Barbara Küppers-Munther, Josefina Edsbagge
  • Patent number: 10098909
    Abstract: The invention relates to a pharmaceutical composition comprising an ionic co-crystal (ICC) of lithium with salicylic acid and 1-proline (LISPRO). The pharmaceutical composition can further comprise an anti-inflammatory agent, for example, salicylic acid. An embodiment of the invention provides a method for treating Fragile X Syndrome (FXS) in a subject by administering to the subject a composition comprising a pharmaceutically effective amount of LISPRO.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: October 16, 2018
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Jun Tan, Roland Douglas Shytle
  • Patent number: 9908879
    Abstract: The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R4 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: March 6, 2018
    Assignee: Asana Biosciences, LLC
    Inventors: Scott K. Thompson, Aranapakam Venkatesan, Tony Priestley, Mrinal Kundu, Ashis Saha
  • Patent number: 9687440
    Abstract: Compositions comprising at least one ingredient that stimulates, enhances, or increases CGRP expression, and a physiologically- or cosmetically-acceptable vehicle. The ingredient may be a compound, natural ingredient, such as a plant or fungus, derivatives, analogs, mimetics, synthetics and the like that stimulates CGRP expression. The CGRP plant includes plants, plant materials, plant extracts, synthetics, or combinations thereof that stimulate CGRP expression. The disclosure is also directed to methods of using the CGRP compositions for decreasing, reducing, or inhibiting fine lines or wrinkled skin.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: June 27, 2017
    Assignee: Avon Products, Inc
    Inventors: John W. Lyga, Laurence Dryer
  • Patent number: 9545446
    Abstract: This invention provides a method of colonic cleansing.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: January 17, 2017
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Dennis Riff, Gary S. Jacob, Kunwar Shailubhai, Patrick H. Griffin
  • Patent number: 9186318
    Abstract: Provided in the present invention is a quinolyl-containing hydroxamic acid compound as shown in formula (I), at the same time also disclosed is the preparation method of the compound and the use thereof, and a pharmaceutical composition containing the quinolyl-containing hydroxamic acid compound. Such compounds are inhibitors of protein kinases and/or histone deacetylases, and can be used in the treatment of diseases caused by the abnormal activity of protein kinases and/or histone deacetylases, for example, tumors, etc.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: November 17, 2015
    Assignee: Beijing Konruns Pharmaceutical Co., Ltd
    Inventors: Ziwei Yun, Hongtao Wang
  • Patent number: 9044418
    Abstract: Treating mental illness by administering synthetic isotope-modified lithium compounds: (i) with the lithium-6 isotope making up at least 95% of the total number of lithium atoms in the compound to treat depression and other mental conditions with reduced alertness levels, (ii) with the lithium-7 isotope making up at least 95% of the total number of lithium atoms in the compound to treat mania and bipolar disorder and other mental illnesses which respond to lithium compounds with natural isotope abundance levels, (iii) with the lithium-6 isotope ranging from 10% to 95% of the total number of lithium atoms in the compound individually tailored to treat patients with a broad variety of mental disorders, including those in (i) and (ii) above.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: June 2, 2015
    Inventor: Matthew P. A. Fisher
  • Patent number: 9034394
    Abstract: Provided is a method of preparing a red clay processed material using red clay and sodium hydroxide and a red clay processed material having anti-corrosive and virus disinfecting activity. Also, a method of preparing alkali ionized water having excellent anti-bacterial, virus disinfecting and anti-corrosive activity using the red clay processed material, alkali ionized water using the same, and a functional product including the same are provided. The red clay processed material and the method of preparing alkali ionized water using the same can reduce the reaction temperature and reaction time compared to a conventional process, thereby significantly reducing the production cost.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: May 19, 2015
    Assignee: Dongguk University Industry-Academic Cooperation Foundation
    Inventors: Jung-Keug Park, Moon Young Yoon
  • Publication number: 20150118180
    Abstract: Formulations containing reactive oxygen species (ROS), processes for making these formulations, and methods of using these formulations are described. The formulations can include gels or hydrogels that contain at least one reactive oxygen species (ROS). The formulations can include a composition containing a reduced species (RS) and a reactive oxygen species (ROS). The formulations can also contain a rheology modifier and can include gels or hydrogels. Methods of preparing the formulations can include preparing a composition. Compositions can be prepared by providing water, purifying the water to produce ultra-pure water, combining sodium chloride to the ultra-pure water to create salinated water, and electrolyzing the salinated water at a temperature between about 4.5 to about 5.8° C.
    Type: Application
    Filed: October 24, 2014
    Publication date: April 30, 2015
    Applicant: REOXCYN DISCOVERIES GROUP, INC.
    Inventor: Andres Hoover
  • Publication number: 20150118327
    Abstract: Compounds, e.g., of formula (I) and (Ia), pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions for treating pain disorders, e.g., disorders associated with cephalic pain, are provided.
    Type: Application
    Filed: October 9, 2014
    Publication date: April 30, 2015
    Inventor: Richard Andrew Sewell
  • Patent number: 9017735
    Abstract: Disclosed herein are compositions and methods for treating a psychiatric disorder or symptoms thereof in a patient. The compositions comprise a compound that modulates KCNQ (Kv7) potassium channel activity and the methods include administering an effective amount of the compound that modulates KCNQ (Kv7) potassium channel activity.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: April 28, 2015
    Assignee: Marquette University
    Inventor: Mohammadhossein Behnam Ghasemzadeh
  • Patent number: 9011931
    Abstract: A composition used to facilitate healing of cold sores, fever blisters and canker sore that includes potassium, rubidium, zinc, calcium and sodium is provided. This composition is compounded into a polyethylene glycol ointment containing allantoin (0.5 to 2 percent) and camphor (0.1 to 3 percent) and/or menthol (0.1 to 1 percent). In another embodiment, a method to treat cold sores, fever blisters and canker sores is provided by applying an effective amount of this composition to cold sores, fever blisters and canker sores of a subject in need of treatment thereof.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: April 21, 2015
    Inventors: Libby Robinson, Mikel Hays
  • Publication number: 20150104528
    Abstract: Treating mental illness by administering synthetic isotope-modified lithium compounds: (i) with the lithium-6 isotope making up at least 95% of the total number of lithium atoms in the compound to treat depression and other mental conditions with reduced alertness levels, (ii) with the lithium-7 isotope making up at least 95% of the total number of lithium atoms in the compound to treat mania and bipolar disorder and other mental illnesses which respond to lithium compounds with natural isotope abundance levels, (iii) with the lithium-6 isotope ranging from 10% to 95% of the total number of lithium atoms in the compound individually tailored to treat patients with a broad variety of mental disorders, including those in (i) and (ii) above
    Type: Application
    Filed: October 10, 2014
    Publication date: April 16, 2015
    Inventor: Matthew P. A. Fisher
  • Publication number: 20150099015
    Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.
    Type: Application
    Filed: November 24, 2014
    Publication date: April 9, 2015
    Inventor: Guochuan Emil TSAI
  • Publication number: 20150099014
    Abstract: The invention provides a biocidal and antifouling composition comprising hydrobromic acid, urea and sodium hypo-chloride from highly concentrated precursors and a process for manufacturing the composition.
    Type: Application
    Filed: March 6, 2013
    Publication date: April 9, 2015
    Inventors: Shlomo Antebi, David Feldman, Chen Zolkov
  • Patent number: 8999297
    Abstract: A generally non-acidic hemostatic agent, having a relatively neutral pH comprising a magnesium compound, such as a magnesium chloride, a magnesium sulfate and/or a magnesium acetate based compound. The resultant agent is generally less caustic than previous agents, when using a similar amount of active material.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: April 7, 2015
    Assignee: Inter-Med, Inc.
    Inventors: Gary J. Pond, John Baeten
  • Patent number: 8968797
    Abstract: Methods of preparing bioactive composites are described. Also described are methods of molding such composites. Shaped bodies comprising bioactive composites are further described.
    Type: Grant
    Filed: September 25, 2007
    Date of Patent: March 3, 2015
    Assignee: Orthovita, Inc.
    Inventors: James P. Murphy, Erik M. Erbe, Charanpreet S. Bagga, Marissa M. Darmoc
  • Publication number: 20150056308
    Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).
    Type: Application
    Filed: June 17, 2014
    Publication date: February 26, 2015
    Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
  • Publication number: 20150050294
    Abstract: The present invention relates to a method for diagnosing neuroendocrine cancers via detecting the presence of N-methyl D-asparate-associated (NMDA) glutamate receptors type 1 and/or type 2. Methods for preventing and treating neuroendocrine cancers are also disclosed.
    Type: Application
    Filed: October 27, 2014
    Publication date: February 19, 2015
    Inventor: William G. North
  • Patent number: 8957027
    Abstract: The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased susceptibility to certain unwanted side effects such as cardiac side effects. In some embodiments, the invention provides methods of administering DAC or DAC inhibitor therapy that includes electrolyte supplementation.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: February 17, 2015
    Assignee: Celgene Corporation
    Inventors: William McCulloch, Richard L. Piekarz, Susan E. Bates
  • Patent number: 8956667
    Abstract: Methods of preparing compositions for preferential distribution of active agents to injury sites are provided. The compositions may comprise a polymer with hydrophilic properties and one or more active agents, such as compounds comprising hydrophilic metal ions. Because the delivery ligand and the active agent are specifically selected so the interactions between them are mainly of an ionic nature. Methods of identifying suitable components for such compositions are also disclosed.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: February 17, 2015
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Josee Roy, Victor Kelley, Roger E. Harrington
  • Publication number: 20150044261
    Abstract: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and methods of synthesizing conjugates of the present technology are also provided. Methods of treating patients with the compositions of the present technology are also provided.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 12, 2015
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Publication number: 20150037380
    Abstract: A skin smoothing film made from a skin smoothing composition that comprises sodium silicate, polyvalent silicate and water. Moreover, the film may be made from a composition that has a contraction value of from about 30% to about 160%. The film thickness is from about 5 microns to about 50 microns, preferably from about 10 microns to about 40 microns, when applied. The standard deviation of the film over the area covered is less than about 30, preferably less than about 25.
    Type: Application
    Filed: July 15, 2014
    Publication date: February 5, 2015
    Inventors: Amanda Leigh NEWMAN, Nancy Lorincz LEPPLA, Laurie Ellen BREYFOGLE, Gordon Gerald GUAY, David Edward WILSON, Joseph Michael ZUKOWSKI
  • Patent number: 8945607
    Abstract: A method of managing dehydration in an animal includes administering a first electrolyte solution having an SID range at or below 25 mEq/l. After administering the first electrolyte solution, the animal's health condition is observed to determine the effect of the first solution. If the animal's health condition has not sufficiently improved, a second solution comprising the first electrolyte solution supplemented with a second electrolyte supplement is administered to the animal wherein the second electrolyte supplement raises the SID of the second solution to at least 50 mEq/l.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: February 3, 2015
    Assignee: Purina Animal Nutrition LLC
    Inventors: Thomas Johnson, Bill L. Miller
  • Publication number: 20150030704
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: August 21, 2012
    Publication date: January 29, 2015
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: William Farnaby, Charlotte Fieldhouse, Katherine Hazel, Catrina Kerr, Natasha Kinsella, David Livermore, Kevin Merchant, David Miller
  • Publication number: 20150024070
    Abstract: A treatment and prevention formulation for canker sores of the oral cavity including an aqueous alkaline solution having at least three B vitamins, zinc and iron mixed therein and administered to a target area by a spray container. The vitamins are B6, B9 and B12, but may include other vitamins as well. The formulation is all-natural, non-toxic and completely ingestible, so it may be used almost anywhere and at almost any time and can be swallowed after use.
    Type: Application
    Filed: July 18, 2013
    Publication date: January 22, 2015
    Inventors: Plato Chun-Chih Lee, Arthur Joseph Dietrich
  • Publication number: 20150024071
    Abstract: The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.
    Type: Application
    Filed: September 30, 2014
    Publication date: January 22, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Scott Wolkenberg, Scott T. Harrison, James C. Barrow, Zhijan Zhao, Jeffrey Melamed, Nathan R. Kett, Amy Zartman
  • Publication number: 20150017260
    Abstract: A nutritional supplement composition for treating nutritional deficiencies caused by a medical condition in subjects is disclosed. The present application further discloses a method of using a nutritional supplements composition for treating a subject with complications resulting from sickle cell anemia. The method comprises administering to a subject an effective amount of the nutritional supplement.
    Type: Application
    Filed: July 28, 2014
    Publication date: January 15, 2015
    Inventors: Jacqueline M. Hibbert, Jonathan K. Stiles, Kayellen Umeakunne, Hyacinth I. Hyacinth
  • Publication number: 20150017266
    Abstract: Compositions and methods for relieving symptoms of rheumatoid arthritis (RA) and related illnesses are disclosed. It appears that the primary cause of RA is a sensitivity or hypersensitivity to potassium and/or vitamin C, or too much potassium and/or vitamin C in the diet. The effects of potassium and vitamin C on the body must be modified to relieve the symptoms of RA and related illnesses. It appears that magnesium does not cause the inflammation, but appears that it exacerbates the problem. It appears that calcium and vitamin D intake, possibly in combination with the reduced or no intake of potassium and/or vitamin C, may also help to relieve the symptoms of RA and related illnesses.
    Type: Application
    Filed: October 2, 2014
    Publication date: January 15, 2015
    Inventor: LUCILLE TOWNSEND
  • Publication number: 20150010663
    Abstract: The present disclosure consists of therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations described herein perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.
    Type: Application
    Filed: September 22, 2014
    Publication date: January 8, 2015
    Applicant: Cosmederm Bioscience, Inc.
    Inventor: Gary S. HAHN
  • Patent number: 8927002
    Abstract: The invention relates to a stent with in particular a coated basic body made of an implant material the use of lithium salts as a coating material or a component of an implant material for stents and the use of lithium salts in a method for restenosis prevention. The inventive stent having a basic body made of an implant material is characterized in that (i) the basic body has a coating which comprises or consists of a lithium salt, and/or (ii) the implant material is biocorrodible and the basic body contains a lithium salt.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: January 6, 2015
    Assignee: Biotronik VI Patent AG
    Inventor: Eric Wittchow
  • Publication number: 20150004216
    Abstract: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 1, 2015
    Inventor: Robert Steven Davidson
  • Publication number: 20140377379
    Abstract: The present invention relates to the prediction of the age-at-onset of Huntington's disease. More specifically, it relates to the use of at least one FoxO-centered network related biallelic markers, preferably single nucleotide polymorphism (SNP) markers, in particular GSK-3? and/or TCERG1 and/or FOXO1 and/or FZD10 related biallelic markers, for prognosing the age-at-onset of symptoms of Huntington's disease in an individual at risk of suffering from said disease.
    Type: Application
    Filed: September 2, 2011
    Publication date: December 25, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventor: Christian Neri
  • Publication number: 20140377380
    Abstract: Disclosed is a treatment of diabetes insipidus. Methods of treating diabetes insipidus disorders associated with P2Y receptors using the compounds and compositions are also disclosed.
    Type: Application
    Filed: August 29, 2012
    Publication date: December 25, 2014
    Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Bellamkonda K. Kishore, Noel G. Carlson, Yue Zhang
  • Publication number: 20140377376
    Abstract: The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water, a sodium containing concentrate, and a bicarbonate containing concentrate into a ready-for-use dialysis solution. Said dialysis acid precursor composition consists of powder components comprising glucose, at least one dry acid and at least one calcium salt, and optionally potassium salt, and magnesium salt. According to the invention said glucose and said at least one calcium salt, are present as anhydrous components in said dialysis acid precursor composition.
    Type: Application
    Filed: June 11, 2012
    Publication date: December 25, 2014
    Applicant: Gambro Lundia AB
    Inventors: Olof Jansson, Torbjorn Linden, Anders Wieslander
  • Publication number: 20140377381
    Abstract: The present invention provides edible compositions comprising a compound of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of NaCl in a food product, methods of reducing the sodium intake in a diet, and methods of reducing bitter taste in a food product.
    Type: Application
    Filed: October 20, 2011
    Publication date: December 25, 2014
    Applicants: KRAFT FOODS GROUP BRANDS LLC, CHROMOCELL CORPORATION
    Inventors: Francis Xavier Brennan, William P. Jones, Jane V. Leland, David Hayashi
  • Patent number: 8911724
    Abstract: Provided are methods and compositions for increasing CD4+ cell count in mammals, preferably by at least 25%, while undergoing treatment for various conditions whose treatment can have detrimental effects on immune system function. Such conditions include, but are not limited to, HIV infection, cancer, and hepatitis. The compositions include alpha lipoic acid; acetyl L-carnitine; N-acetyl-cysteine; and optionally: zinc, selenium, vitamin C, bioflavinoid complex, vitamin E, co-enzyme Q10, glutathione, beta-carotene, vitamin A, vitamin B1, vitamin B2, vitamin B6, niacinamide, calcium pantothenate, folic acid, vitamin B12, copper, manganese, chromium, and molybdenum.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: December 16, 2014
    Assignee: K-PAX Pharmaceuticals, Inc.
    Inventor: Jon D. Kaiser
  • Patent number: 8900604
    Abstract: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and methods of synthesizing conjugates of the present technology are also provided. Methods of treating patients with the compositions of the present technology are also provided.
    Type: Grant
    Filed: March 9, 2011
    Date of Patent: December 2, 2014
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Sanjib Bera
  • Publication number: 20140348956
    Abstract: A scleral lens solution comprising an aqueous mixture that includes sodium, potassium, calcium and magnesium cations and a pH in a range from about 6.5 to about 8.7.
    Type: Application
    Filed: May 22, 2014
    Publication date: November 27, 2014
    Inventor: Ralph P. Stone
  • Publication number: 20140335080
    Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, J1, J2, X, Z, n1 and n2 are as defined herein, and wherein at least one of R1, R2 or R3 is an alkyl, alkenyl, aryl or aralkyl ester, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.
    Type: Application
    Filed: May 9, 2014
    Publication date: November 13, 2014
    Applicants: The University of British Columbia, British Columbia Cancer Agency Branch
    Inventors: Raymond J. Andersen, Marianne D. Sadar, Javier Garcia Fernandez, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos
  • Patent number: 8883762
    Abstract: The present invention provides a solution for peritoneal dialysis, consisting of at least two single solutions which are combined after a heat sterilization and are administered to a patient, the first single solution containing an osmotic and the second single solution containing a buffer, and one of these single solutions or another single solution containing electrolyte salts. Glucose-like degradation and hydrolysis is avoided during sterilization and storage, while maintenance of a neutral mixture pH is achieved by the osmotic comprising a glucose polymer and/or glucose polymer derivative, and the pH of the first single solution being between 3.5 and 5.0. The present invention further discloses a twin-chambered pouch consisting of a plastic pouch with at least one first chamber and a second chamber, the first single solution being included in the first chamber and the second single solution being included in the second chamber.
    Type: Grant
    Filed: March 3, 2008
    Date of Patent: November 11, 2014
    Assignee: Fresenius Medical Care Deutschland GmbH
    Inventor: Thomas Zimmeck
  • Publication number: 20140328949
    Abstract: The present invention provides a method for generating an Enhanced Electrolyzed Alkaline Water solution or hydrogel formulation containing a pH of approximately 12.5 and a Sodium Hydroxide concentration between 150 and 200 ppm having excellent sanitizing and disinfecting properties. The invention further provides methods to apply the Sodium Hydroxide solution as hard surface sanitizer and as a fogging medium for sanitizing stables, barns including poultry incubators as replacement of nowadays used chemical cleaning agents or in case of fumigation replacement of formaldehyde. Finally, the invention discloses usage of modified Enhanced Electrolyzed Water formulations for use as topical treatment in veterinary applications for livestock and wherein gelling-agents, dyes, fragrances, foaming agents, biocides, biopesticides may be blended into the Enhanced Alkaline Water to address specific bactericidal or fungal diseases.
    Type: Application
    Filed: May 6, 2013
    Publication date: November 6, 2014
    Applicant: Aquaox, Inc.
    Inventors: Phillip Adams, Michel van Schaik
  • Publication number: 20140319059
    Abstract: Provided herein is a method for reducing down-time in a recreational body of water having a water filtering system and water recirculation system after a potential release of Cryptospridium oocyst and/or Giardia cysts. Also described is a kit for practicing the method for reducing down-time in a recreational body of water that may have a potential release of Cryptospridium oocyst and/or Giardia cysts.
    Type: Application
    Filed: April 25, 2014
    Publication date: October 30, 2014
    Inventor: Michael Joseph Unhoch
  • Publication number: 20140322359
    Abstract: The invention relates to a unique formulated pharmaceutical composition and a novel treatment method of intratumoral injection. The pharmaceutical composition of the invention is the saturated ionic solution of sodium ions and calcium ions (the “medicinal ion bomb”). The invention of intratumoral injection with the “medicinal ion bomb” can be used as the first-line treatment in treating cancer and tumor in nine human organs (carcinoma and tumor of the skin and subcutaneous tissue, breast, prostate, thyroid, lung, liver, genital organ, brain and pancreas) and certain other benign diseases (skin and subcutaneous neoplasm, breast fibrocystic change, benign prostatic hyperplasia and thyroid nodules).
    Type: Application
    Filed: December 4, 2012
    Publication date: October 30, 2014
    Inventor: David L. Liu
  • Publication number: 20140314882
    Abstract: Combinations of compounds are provided that produce a synergistic effect when administered.
    Type: Application
    Filed: June 27, 2014
    Publication date: October 23, 2014
    Inventors: Frederick P. ROTH, Murat COKOL, Hon Nian CHUA
  • Publication number: 20140302141
    Abstract: This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet (1) comprising two external drug-containing layers (2 and 3) in stacked arrangement with respect to and on opposite sides of an oral dosage form (4) that provides a triple combination release of at least one active agent. In one embodiment of the invention the dosage form is an osmotic device. In another embodiment of the invention the dosage form is a gastro-resistant coated core. In yet another embodiment of the invention the dosage form is a matrix tablet. In a different embodiment the dosage form is a hard capsule.
    Type: Application
    Filed: February 24, 2014
    Publication date: October 9, 2014
    Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: FERNANDO G. TONEGUZZO, GLENN A. MEYER, Marcelo A. RICCI, Marcelo A. COPPARI, ANA C. PASTINI, GUSTAVO A. FISCHBEIN
  • Publication number: 20140302170
    Abstract: Described herein are food formulations and methods, which promote sleep.
    Type: Application
    Filed: April 8, 2014
    Publication date: October 9, 2014
    Applicant: Scientific Nutrition Products, Inc.
    Inventors: Robert C. Jones, Caroline Apovian, Bruce R. Bistrian, Judy Phillips
  • Patent number: 8852566
    Abstract: Compositions are provided for preferential distribution of active agents to injury sites. Such compositions may comprise a ligand with hydrophilic properties and one or more active agents, such as compounds comprising hydrophilic metal ions. Because the delivery ligand and the active agent are specifically selected so the interactions between them are mainly of an ionic nature so that binding of the active agent to the delivery ligand and release of the active agent into the target site are not dependent on enzymatic activity. Methods of using such compositions are also disclosed.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: October 7, 2014
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Josee Roy, Toya Kimble
  • Publication number: 20140287154
    Abstract: Reactive compositions are provided, having biocidal and chemical decontamination/neutralization properties, comprising a hygroscopic polymer and an active, which are useful in a variety of commercial, healthcare and military applications and a wide variety of contaminants, including without limitation chemical and biological warfare agents. The reactive compositions are renewable or rechargeable after use by exposure to an additional application of the active and do not require removal, disposal or replacement of the originally applied composition. Methods for preparing and applying the reactive compositions are disclosed.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 25, 2014
    Inventors: Herbert J. Kaiser, Miranda C. Shaver, Timothy Lee Giddens